Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Cytomegalovirus (CMV) seropositivity or seronegativity~* HLA A\*0201 positive OR positive tetramer-binding using CMV peptide 495-503 with HLA A2 subtypes other than HLA A\*0201~* A2-CMV-Tet cells ≤ 10\^8/L~PATIENT CHARACTERISTICS:~* Platelet count within 1.5 times upper level of normal (ULN)~* The following blood and chemistry studies must be normal:~  * Sodium~ * Potassium~ * Chloride~ * Carbon dioxide~ * Glucose~ * BUN~ * Creatinine~ * Uric acid~ * WBC~ * Hemoglobin~ * Hematocrit~* The following studies must be ≤ ULN:~  * Albumin~ * Alkaline phosphatase~ * AST and ALT~ * Lactic dehydrogenase~ * Total bilirubin~* Hepatitis B virus surface antigen negative~* Hepatitis C virus seronegative~* No diagnosis that is associated with immunodeficiency (e.g., HIV)~* No active infection that requires treatment~* No known cardiac disease including hypertension and/or high cholesterol~* No serious abnormalities by EKG (in participants ≥ 50 years of age)~* Not pregnant~* Negative pregnancy test~* Fertile participants must use effective contraception during study and for 6 weeks after the fourth and last dose of vaccine~* No history of allergic reaction to tetanus toxoid~* No history of any of the following:~  * Cancer other than basal cell carcinoma of the skin~ * Depression~ * Allergic diathesis, as defined by a history of asthma~ * Anaphylaxis~ * Generalized urticaria or daily use of antihistamines~ * Episodic (more than once in the past 3 months) inhalational medications including steroidal agents~ * Non-steroidal agents or cromolyn sodium~ * Frequent migraines, defined as 3 or more episodes in the past year~* No prior or concurrent infectious condition~PRIOR CONCURRENT THERAPY:~* More than 6 months since prior participation in a CMV immunotherapy trial~* More than 30 days since prior live vaccine~* More than 2 weeks since prior inactivated vaccine~* No concurrent daily medications for chronic or current illness, except for the following:~  * Thyroid-replacement therapy~ * Estrogen-replacement therapy~ * Dietary vitamins and protein supplements~ * Any medication, as determined by the principal investigator, that is not known or likely to be immunosuppressive~* No surgery in the past 6 months that required general anesthesia~  * Minor procedures (e.g., dental surgery or superficial diagnostics biopsies) allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Participants receive either PADRE-CMV fusion peptide vaccine or tetanus-CMV fusion peptide vaccine subcutaneously (SC) on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.
- Group B (Type: EXPERIMENTAL): Participants receive either PADRE-CMV fusion peptide vaccine in CpG 7909 adjuvant SC or tetanus-CMV fusion peptide vaccine in CpG 7909 adjuvant SC on days 1, 21, 42, and 63 in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete